Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Journal: Journal of medicinal chemistry 20121108
Title: Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Journal: Cancer letters 20120901
Title: Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.
Journal: Journal of proteome research 20120706
Title: CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Journal: Molecular cancer therapeutics 20120401
Title: Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Journal: Journal of medicinal chemistry 20120322
Title: Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.
Journal: Bioorganic & medicinal chemistry letters 20120101
Title: Antitumoral activity of allosteric inhibitors of protein kinase CK2.
Journal: Oncotarget 20111201
Title: 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Journal: Bioorganic & medicinal chemistry letters 20111115
Title: Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.
Journal: Biochemical and biophysical research communications 20111111
Title: Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Journal: Biochemistry 20111004
Title: Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Journal: Molecular and cellular biochemistry 20111001
Title: Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Journal: Journal of medicinal chemistry 20110127
Title: Structural basis of CX-4945 binding to human protein kinase CK2.
Journal: FEBS letters 20110103
Title: Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Journal: International journal of molecular sciences 20110101
Title: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Journal: Cancer research 20101215
Title: Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Title: Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Title: Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
